Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: An application to electronic medical records

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 8, 2011, Pages 849-857

  Toh, Sengwee ^a   García Rodríguez, Luis A ^a   Hernán, Miguel A ^b,c  

^a Centro Español de Investigación Farmacoepidemiológica ^*  (Spain)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Confounding; Databases; Pharmacoepidemiology; Propensity score analysis; THIN

Indexed keywords

ACECLOFENAC; ACEMETACIN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENBUFEN; FENCLOFENAC; FENOPROFEN; FEPRAZONE; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; INDOPROFEN; KETOPROFEN; KETOROLAC; LORNOXICAM; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; SUPROFEN; TENOXICAM; TIAPROFENIC ACID; TOLFENAMIC ACID; UNINDEXED DRUG;

ADULT; AGED; ALCOHOL CONSUMPTION; ALGORITHM; ARTICLE; BILLING AND CLAIMS; BODY MASS; COMPARATIVE STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; DATA BASE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MALE; PHARMACOEPIDEMIOLOGY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; SMOKING; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROPENSITY SCORE; RISK FACTORS;

EID: 79960704238     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2152     Document Type: Article

References (30)

1. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects-advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725-732.
2. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
3. Rubin DB. On the limitations of comparative effectiveness research. Stat Med 2010; 29: 1991-1995; discussion 1996-1997.
4. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512-522.
5. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
6. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12: 171-177.
7. García Rodríguez LA, Ruigómez A. Case validation in research using large databases. Br J Gen Pract 2010; 60: 160-161.
8. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
9. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524.
10. Wasserman L. All of Nonparametric Statistics. Springer: New York, 2006.
11. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-772.
12. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24.
13. Hernández-Díaz S, García Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099.
14. García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001; 3: 98-101.
15. García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570-576.
16. García Rodríguez LA, Hernández-Díaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004; 159: 23-31.
17. Lanas A, García Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
18. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498-506.
19. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-864.
20. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Weaknesses of goodness-of-fit tests for evaluating propensity score models: the case of the omitted confounder. Pharmacoepidemiol Drug Saf 2005; 14: 227-238.
21. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26: 734-753.
22. Joffe MM. Exhaustion, automation, theory, and confounding. Epidemiology 2009; 20: 523-524.
23. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163: 1149-1156.
24. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004; 15: 615-625.
25. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987; 82: 387-394.
26. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-828, 828 e811-815; quiz 768.
27. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1-278, iii.
28. Toh S, Hernán MA. Causal inference from longitudinal studies with baseline randomization. Int J Biostat 2008; 4: Article 22.
29. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008; 19: 766-779.
30. Danaei G, García Rodríguez LA, Logan R, et al. Observational data for comparative effectiveness: An emulation of randomized trials to estimate the effect of statins on primary prevention of coronary heart disease. Stat Methods Med Res (in press).